Announcement follows FDA’s February 2025 decision to grant radiprodil Breakthrough Therapy designation Company remains on track to initiate Phase 3 pivotal trial of radiprodil in mid-2025 “We are ...
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research ...
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has ...
Findings showed there was a median reduction of 86% in countable motor seizure frequency compared with baseline in the seizure cohort. The Food and Drug Administration (FDA) has granted Breakthrough ...
Neurotech International has entered a research collaboration with the University of Sydney to advance its proprietary ...
Research by Victor Ambros, Ph.D., provides new insights into a recently identified class of neurodevelopmental disorders called Argonaute syndromes. Dr. Ambros and colleagues believe their Proceedings ...
LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating ...
Neurodevelopmental disorders are a diverse group of conditions that affect the brain from early development. They include attention-deficit hyperactivity disorder (ADHD), autism, and learning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results